MELAS Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Khondrion BV, Astellas Pharma Inc, PTC Therapeutics Inc, Tisento Therapeutics, Abliva AB

DelveInsight's "MELAS Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the MELAS Syndrome, historical and forecasted epidemiology as well as the MELAS Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the MELAS Syndrome Market Share @ MELAS Syndrome Market Outlook- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the MELAS Syndrome Market Report
• In March 2025, PTC Therapeutics announced a study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
• In March 2025, Tisento Therapeutics conducted PRIZM study is evaluating 2 dose levels of zagociguat in a crossover design consisting of two 12-week treatment periods separated by a 4-week washout. Patients will be screened and if eligible, randomly assigned either to receive placebo in period 1 followed by active drug in period 2 OR to receive active drug in period 1 followed by placebo in period 2.
• According to Pia et al. (2021), MELAS is one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000. Both genders are equally affected, but only women can pass the condition on as mitochondria are carried in the tails of sperm cells and therefore shed outside the zygote during fertilization.
• A study conducted in Northern England determined that the prevalence of the m.3243A>G variant in the adult population was approximately 1 in 13,000.
• A study estimated that the prevalence of MELAS Syndrome among the general adult population in Spain is about 5.7 cases per 100,000 individuals.
• In 2012, the MELAS syndrome Prevalence was found to be approximately 0.18/100,000 in the total population of Japan.
• A comprehensive study in 2006 revealed a prevalence of the MELAS m.3243A>G variation to be 236/100,000, significantly higher than previously reported estimates.
• The increase in MELAS Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the MELAS Syndrome Market is anticipated to witness growth at a considerable CAGR.
• The leading MELAS Syndrome Companies such as Khondrion BV, Astellas Pharma Inc, PTC Therapeutics Inc, Tisento Therapeutics, Abliva AB, and others.
• Promising MELAS Syndrome Pipeline Therapies such as OMT-28, Vatiquinone, KH176, Zagociguat 30mg, Idebenone and others.

Stay ahead in the MELAS Syndrome Therapeutics Market with DelveInsight's Strategic Report @ MELAS Syndrome Market Outlook- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

MELAS Syndrome Epidemiology Segmentation in the 7MM
The epidemiology section of MELAS Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total MELAS Syndrome Prevalent Cases
• Total MELAS Syndrome Diagnosed Prevalent Cases
• MELAS Syndrome Mutation-specific Diagnosed Prevalent Cases
• MELAS Syndrome Treated Cases

Download the report to understand which factors are driving MELAS Syndrome Epidemiology trends @ MELAS Syndrome Prevalence- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

MELAS Syndrome Emerging Drugs
• Sonlicromanol: Khondrion BV
Khondrion's lead investigational asset, sonlicromanol (formerly known as KH176), stands out as a potential first-in-class medicine and represents one of the most advanced disease-modifying candidates for primary mitochondrial disease currently in clinical development. This innovative therapy is designed to address the fundamental mechanisms underlying mitochondrial disease through its unique triple mode of action, which includes modulation of both reductive and oxidative stress as well as anti-inflammatory effects. Sonlicromanol has received Orphan Drug Designation for MELAS in Europe and all inherited mitochondrial respiratory chain disorders in the US. Additionally, it has been awarded the Rare Pediatric Disease designation by the US FDA for MELAS.

• Zagociguat: Tisento Therapeutics
Zagociguat is an oral, once-daily investigational medication under development for mitochondrial diseases, starting with MELAS syndrome. As a clinical-stage sGC stimulator with CNS-penetrant properties, Zagociguat has demonstrated promising results in clinical studies, including rapid improvements in cerebral blood flow, functional brain connectivity, and cognitive performance. Additionally, the drug has positively influenced biomarkers related to mitochondrial function and inflammation.

• KL1333: Abliva AB
KL1333 is being developed as a treatment for a subset of adult primary mitochondrial disease patients who experience multiple debilitating symptoms, including chronic fatigue and myopathy. The compound functions as a potent modulator of NAD+ and NADH, essential co-enzymes involved in cellular energy metabolism. In a Phase Ia/b study, patients receiving KL1333 demonstrated notable improvements in fatigue and functional status. KL1333 is now under evaluation in a global, potentially registrational Phase II study, known as the FALCON study, and has been granted orphan drug designation in both the US and Europe, along with fast-track designation in the US.

• CY6463 (Cyclerion therapeutics) has completed two Phase I studies on healthy and old (>65 years) volunteers confirming targeting CNS exposure and activity. The status of the study as of May 2021 represents an ongoing phase of development and does not correspond to any particular phase of completion.

• KL1333 (Abliva AB) has been evaluated in healthy volunteers and patients and has been granted Orphan Drug designation in both the United States and Europe. Abliva plans to recruit the first patient in a registrational Phase II/III study in 2022. KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell's energy metabolism.

MELAS Syndrome Drugs Market
The MELAS Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying MELAS Syndrome signaling in MELAS Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients.

MELAS Syndrome Treatment Market Landscape
The MELAS Syndrome treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of MELAS Syndrome has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about MELAS Syndrome treatment guidelines, visit @ MELAS Syndrome Treatment Market Landscape- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

MELAS Syndrome Market Outlook
Anticonvulsant medications are often used to prevent seizures that can occur with MELAS. The symptomatic treatment of seizures is done with anti-epileptic medications. There are several case reports of aggravation of MELAS epilepsy with the use of valproate, though the mechanisms behind this interaction are still being investigated. However, they are unable to confirm the condition via genetic diagnosis. Such instances are further complicated by the aforementioned uncertainty, leading to delays in treatment and subsequent deterioration in the patient's quality of life.

MELAS Syndrome Drugs Uptake
The drug chapter of the MELAS Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to MELAS Syndrome.

Major MELAS Syndrome Companies
Khondrion BV, Astellas Pharma Inc, PTC Therapeutics Inc, Tisento Therapeutics, Abliva AB, and others.

Learn more about the FDA-approved drugs for MELAS Syndrome @ Drugs for MELAS Syndrome Treatment- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the MELAS Syndrome Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• MELAS Syndrome Companies- Khondrion BV, Astellas Pharma Inc, PTC Therapeutics Inc, Tisento Therapeutics, Abliva AB, and others.
• MELAS Syndrome Pipeline Therapies- OMT-28, Vatiquinone, KH176, Zagociguat 30mg, Idebenone and others.
• MELAS Syndrome Market Dynamics: MELAS Syndrome Market Drivers and Barriers
• MELAS Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about MELAS Syndrome Drugs in development @ MELAS Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/melas-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. MELAS Syndrome Executive Summary
3. MELAS Syndrome Competitive Intelligence Analysis
4. MELAS Syndrome: Market Overview at a Glance
5. MELAS Syndrome: Disease Background and Overview
6. Patient Journey
7. MELAS Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. MELAS Syndrome Unmet Needs
10. Key Endpoints of MELAS Syndrome Treatment
11. MELAS Syndrome Marketed Products
12. MELAS Syndrome Emerging Therapies
13. MELAS Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: MELAS Syndrome Market Outlook
16. Access and Reimbursement Overview of MELAS Syndrome
17. KOL Views
18. MELAS Syndrome Market Drivers
19. MELAS Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.